Notice of clarification to drug manufacturers and sponsors: Canadian-specific considerations in risk management plans

We are issuing this notice to help drug manufacturers and sponsors when preparing the Canadian-specific considerations and elements in the risk management plans (RMPs) for certain drug products. This notice describes what is required for certain drug products.

Data and Resources

Additional Info

Field Value
Source
Version
Author
Author Email
Maintainer
Maintainer Email
Data Level
Agreement Required
Purpose Constraints
Redistribution Allowed
AI Training Allowed
Data Steward
Title (French) Avis de clarification aux fabricants et aux promoteurs de médicaments : Considérations propres au contexte canadien dans les plans de gestion des risques
Update Frequency as_needed
Geographic Scope []
Criticality Level []
Sensitivity Level unrestricted
Language
Contact Person
Contact Email
Data Dictionary
Open Canada Date Published 2020-11-09 00:00:00
Open Canada Date Modified
Open Canada Subject ["health_and_safety"]
Open Canada Keywords {"fr": ["Avis de clarification", "fabricants de médicaments", "promoteurs", "considérations spécifiques au Canada", "plans de gestion des risques", "certains produits médicamenteux"], "en": ["Notice of clarification", "drug manufacturers", "sponsors", "Canadian-specific considerations", "risk management plans", "certain drug products"]}
Open Canada Collection publication
Principal Organization
Reference Data
Official Source